NVAX
NVAX
NASDAQ · Biotechnology

Novavax Inc

$10.11
+0.11 (+1.10%)
As of Sep 20, 10:12 PM ET ·
Financial Highlights (FY 2026)
Revenue
1.13B
Net Income
444.72M
Gross Margin
93.5%
Profit Margin
39.2%
Rev Growth
-17.2%
D/E Ratio
0.75
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 93.5% 93.5% 63.1% 63.1%
Operating Margin 37.7% 34.0% -1.5% -1.6%
Profit Margin 39.2% 37.2% -1.5% -1.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.13B 1.37B 441.16M 496.93M
Gross Profit 1.06B 1.28B 278.28M 313.45M
Operating Income 428.36M 465.84M -6,707,375 -7,754,591
Net Income 444.72M 483.63M -6,729,988 -7,016,912
Gross Margin 93.5% 93.5% 63.1% 63.1%
Operating Margin 37.7% 34.0% -1.5% -1.6%
Profit Margin 39.2% 37.2% -1.5% -1.4%
Rev Growth -17.2% -17.2% +6.7% +13.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 351.90M 351.90M 676.10M 713.41M
Total Equity 471.59M 471.59M 690.04M 696.43M
D/E Ratio 0.75 0.75 0.98 1.02
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 456.22M 523.70M -8,036,743 -8,599,324
Free Cash Flow -9,195,591 -10,064,458